[(3R)-3-azaniumyl-4-(3-hexylanilino)-4-oxobutyl]-hydroxyphosphinate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(3R)-3-azaniumyl-4-(3-hexylanilino)-4-oxobutyl]-hydroxyphosphinate
• 化学式: C₁₆H₂₇N₂O₄P
• 分子量: 342.37
• InChiKey: FWJRVGZWNDOOFH-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• [EN] NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF SPHINGOLIPID SIGNALING AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES COMME MODULATEURS DE SIGNALISATION DES SPHINGOLIPIDES ET LEURS UTILISATIONS
  申请人：UNIV JW GOETHE FRANKFURT MAIN

  公开号：WO2012131096A1

  公开（公告）日：2012-10-04

  The present invention relates to new heterocyclic compounds as modulators of sphingolipid signaling and uses thereof as pharmaceutically active agents, suitable for treating proliferative, degenerative, infectious, and other diseases.

  本发明涉及新的杂环化合物，作为鞘脂信号调节剂和作为药物活性剂的用途，适用于治疗增殖性、退行性、感染性和其他疾病。
• Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
  申请人：Johann Wolfgang Goethe-Universität Frankfurt am Main

  公开号：EP2505589A1

  公开（公告）日：2012-10-03

  The present invention relates to new sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof as pharmaceutically active agents, suitable for treating proliferative, degenerative, infectious, and other diseases. wherein X is selected from a methylene group (CH2) and oxygen (O); and pharmaceutically acceptable salts thereof.

  本发明涉及新的鞘脂异环化合物，作为鞘脂信号调节剂和药用活性剂的用途，适用于治疗增殖性、退行性、感染性和其他疾病。其中X选自亚甲基基（CH2）和氧（O）；以及其药学上可接受的盐。
• PHARMACEUTICAL COMPOSITION, METHODS FOR PREPARING AND USING THE SAME
  申请人：National Cheng Kung University

  公开号：EP3412281A1

  公开（公告）日：2018-12-12

  An interspinous stabilizer, comprising: an interspinous spacer, comprising a central support, having a first direction and a second direction opposite to each other, and an upper side and a lower side perpendicular to the first direction and the second direction; an upper side wing is on the first direction and extending from the upper side of the central support; a lower side wing is on the first direction and extending from the lower side of the central support; an upper protrusion is on the second direction and extending from the upper side of the central support; a lower protrusion is on the second direction and extending from the lower side of the central support; at least one perforation, the perforation traversing through the first direction to the second direction of the central support.

  一种棘间稳定器，包括一个棘间稳定器，包括一个中心支架，其第一方向和第二方向彼此相反，上侧和下侧垂直于第一方向和第二方向；一个上侧翼位于第一方向上，从中心支架的上侧延伸；一个下侧翼位于第一方向上，从中心支架的下侧延伸；一个上突起位于第二方向上，从中央支架的上侧延伸出来；一个下突起位于第二方向上，从中央支架的下侧延伸出来；至少一个穿孔，穿孔穿过中央支架的第一方向到第二方向。
• Pharmaceutical composition and methods for using the same
  申请人：NATIONAL CHENG KUNG UNIVERSITY

  公开号：US10806801B2

  公开（公告）日：2020-10-20

  A pharmaceutical composition includes a plurality of metal nanoparticles and at least one therapeutic agent. Each of the metal nanoparticles includes a core and a stabilizing agent coated on a surface of the core. The at least one therapeutic agent is attached to the stabilizing agent of the metal nanoparticles. Each of the therapeutic agent is an amphiphilic compound and has at least one hydrophobic chain interacting with the stabilizing agent. The pharmaceutical composition may further include a polymer shell encapsulating the metal nanoparticles and the therapeutic agent for enabling controlled release of the therapeutic agent. The pharmaceutical compositions are bifunctional and may be used for diagnosing and treating cancer. Methods for using the pharmaceutical compositions in conjunction with radiation therapy to diagnose and treat cancer are also provided.

  一种药物组合物包括多个金属纳米粒子和至少一种治疗剂。每个金属纳米粒子都包括一个核心和涂在核心表面的稳定剂。至少一种治疗剂附着在金属纳米颗粒的稳定剂上。每种治疗剂都是两性化合物，至少有一条疏水链与稳定剂相互作用。药物组合物可进一步包括包裹金属纳米粒子和治疗剂的聚合物外壳，以实现治疗剂的控制释放。药物组合物具有双重功能，可用于诊断和治疗癌症。还提供了结合放射治疗使用药物组合物诊断和治疗癌症的方法。
• NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF SPHINGOLIPID SIGNALING AND USES THEREOF
  申请人：Johann Wolfgang Goethe-Universität

  公开号：EP2694519A1

  公开（公告）日：2014-02-12